For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
State Directed Payments redistribute money across states and supercharged growth
Differences in states’ use of SDPs cause an interstate redistribution of taxes as well. Because states are setting different levels of SDPs, spending varies…
Blog
How State Directed Payments turned Medicaid into an interstate transfer scheme
Medicaid’s financing rules have long allowed states to expand spending while shifting much of the cost to federal taxpayers. One of the most important…
Blog
Medicaid financing gimmickry – before and after the One Big Beautiful Bill
Medicaid was created in 1965 as a joint federal-state health insurance program for low-income individuals which targeted families with dependent children, the elderly, and…
Search Posts
Comment
Letter to OIRA Re: Request for OIRA to Resolve Interagency Disagreement Concerning IQA Implementation About Medical Marijuana
The Competitive Enterprise Institute (CEI) requests that OIRA resolve a dispute between two different agencies concerning responsibility for ensuring compliance with the Information Quality…
The New York Post
Politicians Are Using Omicron as an Excuse to Return to their Autocratic Ways
Since the start of the pandemic, governors around the country have often struggled to appear to be doing something to stem COVID-19, regardless of…
City Journal
One Size Doesn’t Fit All
In a rebuke of the Biden administration, the Fifth Circuit Court of Appeals reaffirmed its stay of the Occupational Safety and Health Administration’s (OSHA)…
The New York Post
A Reality Check on How we Handle COVID-19 Risks
COVID-19 is still with us. Cases are rising in Europe and to a smaller extent in this country. But the fact that SARS-CoV-2, the…
Letters
CEI Joins ATR Led Drug Price Control Coalition Letter
Dear Member of Congress: We write in opposition to the Democrat plan to impose price controls, a 95 percent excise tax, and inflation…
National Review
What’s Taking the FDA So Long on COVID Drug Molnupiravir?
On October 1, pharmaceutical companies Merck and Ridgeback Biotherapeutics announced that their investigational oral antiviral drug Molnupiravir reduced the risk of hospitalization or…
